Background
Methods
Study design and data source
Study variables
Statistical analyses
Results
Patients
Patients (N = 808) | |
---|---|
Gender, n (%) | |
Male | 499 (61.8) |
Female | 309 (38.2) |
Age groups, n (%) | |
< 50 | 168 (20.8) |
50–60 | 197 (24.4) |
60–75 | 311 (38.5) |
> 75 | 132 (16.3) |
Origin of the patient, n (%) | |
Primary healthcare | 340 (42.1) |
Specialized healthcare | 468 (57.9) |
Anticoagulant agent, n (%) | |
Acenocoumarol | 791 (97.9) |
Warfarin | 17 (2.1) |
Target INR, n (%) | |
2.0–3.0 | 610 (75.5) |
2.5–3.5 | 182 (22.5) |
Other | 16 (2.0) |
Indication for anticoagulation, n (%) | |
Mechanical heart valve | 204 (25.2) |
Atrial fibrillation/ Atrial flutter | 344 (42.6) |
Venous and arterial thrombosis | 111 (13.7) |
Others | 148 (18.3) |
Unknown | 1 (0.1) |
Time of follow-up, median years (IQR) | 3.3 (0.0–5.0) |
Required a responsible caregiver to PSM a | 107 (14.0) |
Study withdrawal, n (%) | 177 (21.9) |
Death | 59 (7.3) |
End of treatment | 42 (5.2) |
Never performed PSM | 36 (4.5) |
Voluntary withdrawal | 28 (3.5) |
Loss to follow-up | 8 (1.0) |
Others | 4 (0.5) |
Effectiveness of PSM
Median time in therapeutic range (%) | P | |
---|---|---|
Overall (n = 476) a | 71.5 | |
Gender | < 0.026 | |
Male | 70.6 | |
Female | 72.6 | |
Target INR | < 0.001 | |
2.0–3.0 | 73.9 | |
2.5–3.5 | 65.6 | |
Other | 67.6 | |
Indication for anticoagulation | < 0.001 | |
Mechanical heart valve (n = 125) | 67.2 | |
Atrial fibrillation/ Atrial flutter (n = 178) | 73.5 | |
Venous and arterial thrombosis (n = 57) | 73.1 | |
Others (n = 93) | 71.7 |
Safety of PSM
Discussion
Author | Number of patients | Indication | Median Years of follow-up | Mortality a | Thromboembolic events a | Major hemorrhages a | Median TTR (%) |
---|---|---|---|---|---|---|---|
Fritschi et al., [24] | 300 | Mixed | 2.8 | – | 0.6 | 0.6 | 72.0 |
Matchar et al., [25] | 1463 | AF, MHV | 3.0 b | 3.4 | 0.7 | 4.0 | 66.2 |
Nagler et al., [26] | 1221 | Mixed | 4.3 | 1.4 | 0.9 | 1.2 | 80.0 |
Ward et al., [27] | 296 | Mixed | 1.0 | – | – | – | 75.3 b |
Grove et al., [28] | 534 | AF | 2.5 | 1.1 | 0.5 | 2.3 | – |
Present study | 808 | Mixed | 3.3 | 2.4 | 0.9 | 0.5 | 71.5 |
Conclusions
Acknowledgements
Declarations
- All authors of the manuscript have read and agreed to its content and are accountable for all aspects of the accuracy and integrity of the manuscript.
- The article is original, has not already been published in a journal, and is not currently under consideration by another journal.
- I agree to the terms of the BioMed Central Copyright and License Agreement, and Open Data policy.